A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Recruiting now · Phase 3

Conditions studied: Essential Thrombocythemia

In brief

This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.

Key facts

Study ID

NCT07623200

Run by

Incyte Corporation

People needed

426

Starts

2026-09-08

Expected to finish

2030-11-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of high-risk ET.
• Presence of mutCALR.
• Prior treatment with at least 1 cytoreductive therapy.

You may not qualify if…

• Presence of any hematologic malignancy other than ET.
• Major bleeding or thrombosis within the last 3 months prior to study enrollment.
• Any prior allogenic or autologous stem-cell transplantation.
• Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.
• Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease.
• Other protocol-defined Inclusion/Exclusion Criteria apply.

Where it is running

• Marin Cancer Care — Greenbrae, California, United States (enrolling)
• City of Hope Medical Center — Duarte, California, United States
• The University of Kansas Cancer Center — Westwood, Kansas, United States
• University of California, Los Angeles Medical Center — Los Angeles, California, United States
• Stanford Cancer Center — Palo Alto, California, United States
• UCSF — San Francisco, California, United States
• Rocky Mountain Cancer Centers-Lone Tree — Lone Tree, Colorado, United States
• Medstar Georgetown Medical Center, Inc — Washington D.C., District of Columbia, United States
• Florida Cancer Specialists & Research Institute — Fort Myers, Florida, United States
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Cleveland Clinic — Weston, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois, United States
• University of Chicago — Chicago, Illinois, United States
• The University of Arizona Cancer Center — Tucson, Arizona, United States
• Johns Hopkins Medicine-the Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
• Maryland Oncology Hematology, P.A. — Columbia, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center (Bidmc) — Boston, Massachusetts, United States
• University of Massachusetts Medical School — Worcester, Massachusetts, United States
• University of Michigan Rogel Cancer Center Adult Bone Marrow Transplant Clinic — Ann Arbor, Michigan, United States
• Missouri Cancer Associates — Columbia, Missouri, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey, United States
• Banner Md Anderson Cancer Center — Gilbert, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.